Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Average Rating of “Moderate Buy” by Analysts

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has been given a consensus recommendation of “Moderate Buy” by the four brokerages that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and three have given a buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $7.00.

A number of analysts recently issued reports on SGMO shares. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Sangamo Therapeutics in a report on Thursday, December 19th. Barclays boosted their price objective on shares of Sangamo Therapeutics from $3.00 to $9.00 and gave the company an “overweight” rating in a research note on Thursday, November 14th. Wells Fargo & Company lowered their target price on shares of Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating on the stock in a research note on Tuesday. StockNews.com lowered shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, December 24th. Finally, Truist Financial upgraded Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $7.00 price objective on the stock in a research report on Friday, December 13th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Meritage Portfolio Management increased its holdings in Sangamo Therapeutics by 8.6% during the 3rd quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company’s stock valued at $74,000 after purchasing an additional 6,740 shares during the period. XTX Topco Ltd grew its position in shares of Sangamo Therapeutics by 167.8% in the 3rd quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company’s stock worth $90,000 after buying an additional 64,981 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its stake in shares of Sangamo Therapeutics by 55.4% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company’s stock valued at $94,000 after buying an additional 38,850 shares during the period. Virtu Financial LLC bought a new position in shares of Sangamo Therapeutics during the third quarter valued at approximately $150,000. Finally, Cubist Systematic Strategies LLC purchased a new stake in Sangamo Therapeutics in the second quarter worth $67,000. Institutional investors own 56.93% of the company’s stock.

Sangamo Therapeutics Trading Down 8.6 %

SGMO stock opened at $2.34 on Tuesday. Sangamo Therapeutics has a 1-year low of $0.30 and a 1-year high of $3.18. The stock has a market cap of $488.23 million, a P/E ratio of -3.12 and a beta of 1.15. The stock’s fifty day simple moving average is $2.13 and its two-hundred day simple moving average is $1.21.

Sangamo Therapeutics (NASDAQ:SGMO) last released its earnings results on Tuesday, November 12th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.07. Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. The firm had revenue of $49.41 million during the quarter, compared to the consensus estimate of $26.55 million. During the same period in the prior year, the firm earned ($0.34) EPS. As a group, analysts forecast that Sangamo Therapeutics will post -0.46 earnings per share for the current fiscal year.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.